

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: Fredrik Nicklasson, et al.

EXAMINER: Not Assigned

SERIAL NO. Not Assigned

ART UNIT: Not Assigned

FILED: April 2, 2004

TITLE: New Formulations and Use Thereof

DATE: April 2, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97**


Sir:

Pursuant to 37 CFR. § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached Form PTO-1449, submitted in accordance with attached 37 CFR. §§ 1.98(a)(1) and 1.98 (b). It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein. As this Information Disclosure Statement is filed with the application, it is believed to be timely filed in accordance with 37 CFR §1.97(b)(1).

While no representation is made that any of these references may be "prior art" within the meaning of that term under 35 USC §§ 102 or 103, the enclosed list of references is disclosed so as to fully comply with the duty of disclosure set forth in 37 CFR § 1.56.

**CERTIFICATION PURSUANT TO 37 C.F.R. §1.10**

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this April 2, 2004 date, in an envelope bearing "Express Mail Post Office to Addressee" addressed to the Commissioner of Patents and Trademarks, Alexandria, VA 22313-1450.

  
Mary M. Helmken

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney or agent of record believes that the enclosed art is the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

Date: 4/6/04

Respectfully submitted,



Evan J. Federman  
Attorney for the Applicant  
Reg. No. 37,060

Direct Communications To:

Evan J. Federman  
Warner-Lambert Company, LLC  
201 Tabor Road  
Morris Plains, New Jersey 07950  
Phone (973) 385-5263  
Fax (973) 385-3117  
CUSTOMER NO. 29668

FORM PTO-1449 U.S. DEPARTMENT OF (Rev. 2-32) COMMERCE PATENT & TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)	ATTY. DOCKET NO.  PC27889A	SERIAL NO. Not Assigned
	APPLICANT  Fredrik Nicklasson, et al.	
	FILING DATE April 2, 2004	GROUP Not Assigned

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 3 8 2 6 0 0	1/17/95	Jonsson et al			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 9 8 0 3 0 6 7	1/29/98	PCT				
	WO 0 0 1 2 0 7 0	3/9/00	PCT				

**OTHER DOCUMENTS**

(Including Author, Title, Date, Pertinent Pages, etc)

	"Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine"; Pharmacol. Toxicol. (1997) 81:195-207
	Brynne N, et al.; Clin Pharmacol Ther 1998 (63):529-39

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.